The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Investigating the Molecular Basis of Neurodegeneration in GBA-associated Parkinson's Disease
Study Rationale: Mutations in GBA1, the gene that encodes the enzyme glucocerebrosidase (GCase), are among the most common genetic risk factor for the development of Parkinson’s disease (PD). GCase...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023SUPPLEMENT | CMA as a Means to Counteract Alpha-synuclein Pathology in Non-human Primates”
Study Rationale: One of the main pathways to remove excess amounts of the alpha-synuclein protein that is linked to Parkinson’s disease (PD) is the lysosomal chaperone-mediated autophagy (CMA) pathway...
-
Improved Outcome Measures, 2021Development of PD Biomarkers Using Focused Ultrasound-based Noninvasive Biopsy
Study Rationale: There is an urgent need to develop non-invasive biomarkers that are able to diagnose and track the progression of Parkinson’s disease (PD). Focused ultrasound blood brain barrier...
-
Parkinson's Pathway Biomarkers, 2021Phospho-proteome Analysis of PBMCs in LRRK2 Mutation Carriers: Expansion & Validation of Findings of the Barcelona LRRK2 Biorepository
Study Rationale: We established a biorepository of blood cells from G2019S LRRK2-PD patients recruited at the Hospital Clínic de Barcelona (Barcelona). Using this cohort, we performed a phospho...
-
Lysosomal Biomarkers Program, 2023Validating Measurements of Peripheral GCase Longitudinally Under Clinical Trial Conditions
Study Rationale: An enzyme known as GCase is a key protein that stops working properly in people with Parkinson’s disease (PD). However, determining exactly how impaired the enzyme’s activity might...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Effect of SAR-CoV-2 on Experimental Parkinsonism in a Preclinical Model of Parkinson’s Disease
Study Rationale: Approximately 16.5 million people have been infected with the SARS-CoV2 virus. While primarily a respiratory virus, clinical observations indicate that in many cases, infection is...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.